What is Neurosense Therapeutics Ltd (NRSN) stock price today?

Neurosense Therapeutics Ltd (NRSN) currently trades at $0.80 per share. The stock has a market capitalization of $26.53M and a P/E ratio of —x.

Is NRSN stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Neurosense Therapeutics Ltd has a Smart Value Score of 21/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is -17.80.

Is Neurosense Therapeutics Ltd financially healthy?

Neurosense Therapeutics Ltd's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of -17.80 places it in the distress.

NRSN

Neurosense Therapeutics Ltd

NASDAQ: NRSN · HEALTHCARE · BIOTECHNOLOGY

$0.80

-0.72% today

Updated 2026-04-29

Market cap

$26.53M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.44

Dividend yield

—

52W range

$1 – $3

Volume

0.2M

Market cap

$26.53M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-0.44

Dividend yield

—

52W range

$1 – $3

Volume

0.2M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

3.3

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

-17.8

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$8.38

+943.46%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 3/9 — weak financial health

- Altman Z -17.80 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-7.68M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-12.34M	$-10.11M	$-10.21M	$-11.13M	$-11.13M
EPS	—	—	—	—	$-0.44
Free cash flow	$-7.66M	$-8.38M	$-10.14M	$-7.68M	$-7.68M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NRSN	$26.53M	21	4.3	3.0	5.0	3.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Neurosense Therapeutics Ltd trades at $0.80. Our Smart Value Score of 21/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -17.80, it sits in the distress.

Frequently asked questions

What is Neurosense Therapeutics Ltd's stock price?

Neurosense Therapeutics Ltd (NRSN) trades at $0.80.

Is Neurosense Therapeutics Ltd overvalued?

Smart Value Score 21/100 (Grade F, Strong Sell).

What is the price target of Neurosense Therapeutics Ltd (NRSN)?

The analyst target price is $8.38, representing +943.5% upside from the current price of $0.80.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

-17.80 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-2,175.00%

Beta1.68

50D MA$0.80

200D MA$1.07

Shares out0.04B

Float0.03B

Short ratio—

Avg volume0.2M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NRSN vs LLY →NRSN vs JNJ →NRSN vs ABBV →Stock screener →